971 related articles for article (PubMed ID: 17999270)
1. Management of antipsychotic-induced weight gain: prospective naturalistic study of the effectiveness of a supervised exercise programme.
Poulin MJ; Chaput JP; Simard V; Vincent P; Bernier J; Gauthier Y; Lanctôt G; Saindon J; Vincent A; Gagnon S; Tremblay A
Aust N Z J Psychiatry; 2007 Dec; 41(12):980-9. PubMed ID: 17999270
[TBL] [Abstract][Full Text] [Related]
2. [Drawing up guidelines for the attendance of physical health of patients with severe mental illness].
Saravane D; Feve B; Frances Y; Corruble E; Lancon C; Chanson P; Maison P; Terra JL; Azorin JM;
Encephale; 2009 Sep; 35(4):330-9. PubMed ID: 19748369
[TBL] [Abstract][Full Text] [Related]
3. Effects of a 10-week weight control program on obese patients with schizophrenia or schizoaffective disorder: a 12-month follow up.
Chen CK; Chen YC; Huang YS
Psychiatry Clin Neurosci; 2009 Feb; 63(1):17-22. PubMed ID: 19067997
[TBL] [Abstract][Full Text] [Related]
4. Improvement in antipsychotic-related metabolic disturbances in patients with schizophrenia switched to ziprasidone.
Montes JM; Rodriguez JL; Balbo E; Sopelana P; Martin E; Soto JA; Delgado JF; Diez T; Villardaga I
Prog Neuropsychopharmacol Biol Psychiatry; 2007 Mar; 31(2):383-8. PubMed ID: 17129654
[TBL] [Abstract][Full Text] [Related]
5. Glucose and lipid metabolism of long-term risperidone monotherapy in patients with schizophrenia.
Murashita M; Inoue T; Kusumi I; Nakagawa S; Itoh K; Tanaka T; Izumi T; Hosoda H; Kangawa K; Koyama T
Psychiatry Clin Neurosci; 2007 Feb; 61(1):54-8. PubMed ID: 17239039
[TBL] [Abstract][Full Text] [Related]
6. Effect of treatment on weight gain and metabolic abnormalities in patients with first-episode psychosis.
Verma S; Liew A; Subramaniam M; Poon LY
Aust N Z J Psychiatry; 2009 Sep; 43(9):812-7. PubMed ID: 19670054
[TBL] [Abstract][Full Text] [Related]
7. [Clinical factors related to gains in body mass index (BMI) among patients under long-term antipsychotic treatment].
Koga M
Seishin Shinkeigaku Zasshi; 2003; 105(4):473-88. PubMed ID: 12806910
[TBL] [Abstract][Full Text] [Related]
8. Physical activity is associated with risk factors for chronic disease across adult women's life cycle.
Woolf K; Reese CE; Mason MP; Beaird LC; Tudor-Locke C; Vaughan LA
J Am Diet Assoc; 2008 Jun; 108(6):948-59. PubMed ID: 18502225
[TBL] [Abstract][Full Text] [Related]
9. Oral versus injectable antipsychotic treatment in early psychosis: post hoc comparison of two studies.
Emsley R; Oosthuizen P; Koen L; Niehaus DJ; Medori R; Rabinowitz J
Clin Ther; 2008 Dec; 30(12):2378-86. PubMed ID: 19167596
[TBL] [Abstract][Full Text] [Related]
10. Are psychoactive-drug-induced changes in plasma lipid and lipoprotein levels of significance for clinical remission in psychiatric disorders?
Diebold K; Michel G; Schweizer J; Diebold-Dörsam M; Fiehn W; Kohl B
Pharmacopsychiatry; 1998 Mar; 31(2):60-7. PubMed ID: 9562210
[TBL] [Abstract][Full Text] [Related]
11. Changes in neuroendocrine and metabolic hormones induced by atypical antipsychotics in normal-weight patients with schizophrenia.
Popovic V; Doknic M; Maric N; Pekic S; Damjanovic A; Miljic D; Popovic S; Miljic N; Djurovic M; Jasovic-Gasic M; Dieguez C; Casanueva FF
Neuroendocrinology; 2007; 85(4):249-56. PubMed ID: 17570902
[TBL] [Abstract][Full Text] [Related]
12. Outcome evaluation of a structured educational wellness program in patients with severe mental illness.
Lindenmayer JP; Khan A; Wance D; Maccabee N; Kaushik S; Kaushik S
J Clin Psychiatry; 2009 Oct; 70(10):1385-96. PubMed ID: 19778494
[TBL] [Abstract][Full Text] [Related]
13. Weight loss in overweight patients maintained on atypical antipsychotic agents.
Centorrino F; Wurtman JJ; Duca KA; Fellman VH; Fogarty KV; Berry JM; Guay DM; Romeling M; Kidwell J; Cincotta SL; Baldessarini RJ
Int J Obes (Lond); 2006 Jun; 30(6):1011-6. PubMed ID: 16432547
[TBL] [Abstract][Full Text] [Related]
14. The METEOR study: frequency of metabolic disorders in patients with schizophrenia. Focus on first and second generation and level of risk of antipsychotic drugs.
Falissard B; Mauri M; Shaw K; Wetterling T; Doble A; Giudicelli A; De Hert M
Int Clin Psychopharmacol; 2011 Nov; 26(6):291-302. PubMed ID: 21876442
[TBL] [Abstract][Full Text] [Related]
15. Metabolic syndrome in female patients with schizophrenia treated with second generation antipsychotics: a 3-month follow-up.
Medved V; Kuzman MR; Jovanovic N; Grubisin J; Kuzman T
J Psychopharmacol; 2009 Nov; 23(8):915-22. PubMed ID: 18635691
[TBL] [Abstract][Full Text] [Related]
16. A preliminary investigation of alpha-lipoic acid treatment of antipsychotic drug-induced weight gain in patients with schizophrenia.
Kim E; Park DW; Choi SH; Kim JJ; Cho HS
J Clin Psychopharmacol; 2008 Apr; 28(2):138-46. PubMed ID: 18344723
[TBL] [Abstract][Full Text] [Related]
17. Antipsychotic-associated weight gain and clinical outcome parameters.
Blin O; Micallef J
J Clin Psychiatry; 2001; 62 Suppl 7():11-21. PubMed ID: 11346191
[TBL] [Abstract][Full Text] [Related]
18. The SNAP-25 gene may be associated with clinical response and weight gain in antipsychotic treatment of schizophrenia.
Müller DJ; Klempan TA; De Luca V; Sicard T; Volavka J; Czobor P; Sheitman BB; Lindenmayer JP; Citrome L; McEvoy JP; Lieberman JA; Honer WG; Kennedy JL
Neurosci Lett; 2005 May; 379(2):81-9. PubMed ID: 15823421
[TBL] [Abstract][Full Text] [Related]
19. Metabolic syndrome in bipolar disorder: a cross-sectional assessment of a Health Management Organization database.
Sicras A; Rejas J; Navarro R; Serrat J; Blanca M
Bipolar Disord; 2008 Jul; 10(5):607-16. PubMed ID: 18657245
[TBL] [Abstract][Full Text] [Related]
20. Assessment of a point-of-care metabolic risk screening program in outpatients receiving antipsychotic agents.
Schneiderhan ME; Batscha CL; Rosen C
Pharmacotherapy; 2009 Aug; 29(8):975-87. PubMed ID: 19637951
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
